Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Recessive dystrophic epidermolysis bullosa Indication Strategy Report 2026: COL7A1, Trials and Deals
3 August 2026
2026 Recessive dystrophic epidermolysis bullosa indication strategy covering epidemiology, COL7A1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Harlequin ichthyosis Indication Strategy Report 2026: ABCA12, Trials and Deals
3 August 2026
2026 Harlequin ichthyosis indication strategy covering epidemiology, ABCA12 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Porokeratosis Indication Strategy Report 2026: MVK, Trials and Deals
3 August 2026
2026 Porokeratosis indication strategy covering epidemiology, MVK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Transient acantholytic dermatosis Indication Strategy Report 2026: ATP2A2, Trials and Deals
3 August 2026
2026 Transient acantholytic dermatosis indication strategy covering epidemiology, ATP2A2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Very early onset inflammatory bowel disease Indication Strategy Report 2026: IL-10, Trials and Deals
3 August 2026
2026 Very early onset inflammatory bowel disease indication strategy covering epidemiology, IL-10 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Kindler epidermolysis bullosa Indication Strategy Report 2026: FERMT1, Trials and Deals
3 August 2026
2026 Kindler epidermolysis bullosa indication strategy covering epidemiology, FERMT1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Epidermolysis bullosa simplex Indication Strategy Report 2026: KRT14, Trials and Deals
3 August 2026
2026 Epidermolysis bullosa simplex indication strategy covering epidemiology, KRT14 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Chronic granulomatous disease-associated colitis Indication Strategy Report 2026: NADPH oxidase, Trials and Deals
3 August 2026
2026 Chronic granulomatous disease-associated colitis indication strategy covering epidemiology, NADPH oxidase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
IPEX-associated enteropathy Indication Strategy Report 2026: FOXP3, Trials and Deals
3 August 2026
2026 IPEX-associated enteropathy indication strategy covering epidemiology, FOXP3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Trichohepatoenteric syndrome Indication Strategy Report 2026: TTC37, Trials and Deals
3 August 2026
2026 Trichohepatoenteric syndrome indication strategy covering epidemiology, TTC37 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital tufting enteropathy Indication Strategy Report 2026: EPCAM, Trials and Deals
3 August 2026
2026 Congenital tufting enteropathy indication strategy covering epidemiology, EPCAM biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Cronkhite-Canada syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Cronkhite-Canada syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…